Evaluation of Re/99mTc-labeled somatostatin receptor-targeting peptide complexes synthesized via direct metal cyclization
暂无分享,去创建一个
Heather M. Hennkens | S. Jurisson | G. Makris | F. Gallazzi | Yawen Li | M. Kuchuk | M. Lewis | Jing Wang
[1] Heather M. Hennkens,et al. Direct labeling of a somatostatin receptor antagonist via peptide cyclization with Re, 99mTc and 186Re metal centers: Radiochemistry and in vitro evaluation. , 2021, Nuclear medicine and biology.
[2] A. Hubalewska-Dydejczyk,et al. Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates , 2020, Pharmaceuticals.
[3] P. Loyer,et al. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy , 2020, Molecules.
[4] Adriano Duatti,et al. Review on 99mTc radiopharmaceuticals with emphasis on new advancements. , 2020, Nuclear medicine and biology.
[5] Heather M. Hennkens,et al. Somatostatin receptor targeting with hydrophilic [99mTc/186Re]Tc/Re-tricarbonyl NODAGA and NOTA complexes. , 2019, Nuclear medicine and biology.
[6] J. Reubi,et al. The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist , 2018, EJNMMI Research.
[7] G. Nicolas,et al. Somatostatin Receptor Antagonists for Imaging and Therapy , 2017, The Journal of Nuclear Medicine.
[8] Ashley F. Berendzen,et al. Synthesis and evaluation of a 99mTc tricarbonyl-labeled somatostatin receptor-targeting antagonist peptide for imaging of neuroendocrine tumors. , 2017, Nuclear medicine and biology.
[9] I. Velikyan,et al. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms , 2017, Pharmaceuticals.
[10] Heather M. Hennkens,et al. Synthesis, Characterization, and In Vitro Evaluation of New (99m)Tc/Re(V)-Cyclized Octreotide Analogues: An Experimental and Computational Approach. , 2016, Inorganic chemistry.
[11] Roberto Würth,et al. Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm , 2013, International journal of peptides.
[12] W. Weber,et al. Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications , 2012, The Journal of Nuclear Medicine.
[13] S. Schulz,et al. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[14] J. Reubi,et al. Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro , 2011, The Journal of Nuclear Medicine.
[15] J. Reubi,et al. Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment , 2011, The Journal of Nuclear Medicine.
[16] S. Jurisson,et al. Labeling, stability and biodistribution studies of 99mTc-cyclized Tyr3-octreotate derivatives. , 2011, Nuclear medicine and biology.
[17] S. Jurisson,et al. In vitro structure-activity relationship of Re-cyclized octreotide analogues. , 2010, Nuclear medicine and biology.
[18] C. Cutler,et al. Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. , 2009, Nuclear medicine and biology.
[19] S. Jurisson,et al. Synthesis and in vitro evaluation of a rhenium-cyclized somatostatin derivative series. , 2008, Journal of medicinal chemistry.
[20] R. Rogers,et al. MO tripeptide diastereomers (M=99/99mTc, Re): models to identify the structure of 99mTc peptide targeted radiopharmaceuticals. , 2007, Inorganic chemistry.
[21] Judit Erchegyi,et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.
[22] J. Reubi,et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.
[23] S. Jurisson,et al. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] E. Chiotellis,et al. Syn-Anti Isomerism in a Mixed-Ligand Oxorhenium Complex, ReO[SN(R)S][S]. , 1996, Inorganic chemistry.
[25] A. Camerman,et al. Technetium (V) and rhenium (V) complexes of 2,3-bis(mercaptoacetamido)propanoate. Chelate ring stereochemistry and influence on chemical and biological properties , 1990 .